Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption. Sophia Humphreys, ...
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...
Number 5: By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely ...
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...
Celltrion plans to commercialize 22 biosimilars by 2030, expanding its global presence with robust sales growth driven by ...
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...
Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous ...
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback